Biopharma Quarterly Dealmaking Statistics, Q3 2017
A look at financing, M&A and alliance activity July–September 2017
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
You may also be interested in...
The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city last week, amid heightened excitement around China’s newly issued opinions on deepening reforms to encourage drug innovation including biosimilars. With the favorable opportunities, Amgen is open to establishing more local partnerships as its core China strategy.
The UK developer of gene therapies for inherited eye diseases has listed on NASDAQ, adding to its monetary resources for competing in what is becoming a competitive sector for drug development, and going some way to validating the approach of the UK healthcare investment firm, Syncona, to growing biotech companies.
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.